<DOC>
	<DOCNO>NCT01487577</DOCNO>
	<brief_summary>Bone marrow transplantation ( BMT ) use successfully treat high-risk form leukemia , lymphoma , childhood cancer consider incurable . A major barrier application life-saving treatment acute graft-versus-host disease ( GVHD ) develop approximately 30-80 % patient lead cause death transplant complication . Current GVHD prevention method efficacious lead unacceptable side effect . Mycophenolate mofetil ( MMF ) , anti-rejection medication use solid organ transplant , show great promise BMT recipient . The effectiveness MMF depend blood level mycophenolic acid ( MPA , active form MMF ) . Different patient find different blood level MPA give dose MMF . The purpose study study novel method give MMF base metabolism ( pharmacokinetics ) achieve desire blood level MPA prevention GVHD . Non-invasive way monitor drug exposure also study . The ultimate goal study improve approach GVHD prevention improve outcome BMT child .</brief_summary>
	<brief_title>Pharmacokinetics-based Mycophenolate Mofetil Dosing GVHD Prevention</brief_title>
	<detailed_description>Graft-versus-host disease ( GVHD ) remain major barrier success allogeneic blood marrow transplant ( BMT ) therapy . Acute GVHD see 30-80 % patient establish , often respond poorly therapy associate chronic disease increase risk death . Although combination methotrexate ( MTX ) calcineurin inhibitor `` standard care '' quarter century , little consensus effective least toxic approach GVHD prevention . MTX use associate painful mucositis , delay engraftment potential pulmonary toxicity . For cord blood transplant , commonly , calcineurin inhibitor use corticosteroid antithymocyte globulin . Steroid therapy frequently complicate high rate infection , hyperglycemia hypertension . Mycophenolate mofetil ( MMF ) , whose metabolite mycophenolic acid ( MPA ) inhibit proliferation lymphocyte , approve prevention organ transplant rejection . MMF combination CsA widely use GVHD prevention patient receive reduced-intensity conditioning BMT . It also successfully use primary salvage therapy acute GVHD . In myeloablative transplant , GVHD outcomes appear comparable , regimen appear superior toxicity profile comparison CsA MTX faster hematopoietic engraftment reduce severity duration mucositis . One challenge MMF use BMT recipient significantly low MPA exposure immediate post-conditioning period compare organ transplant recipient . This show number pharmacokinetics study include preliminary data pediatric myeloablative transplant . Low total unbound MPA trough concentration associate high rate acute GVHD graft rejection , low response rate treatment acute GVHD . There also poor correlation MPA trough concentration area concentration curve ( AUC ) . While previous study use fix MMF dosing , one recent study adult show feasibility AUC-based individualize MMF dose . This protocol base premise optimization MPA exposure immediate post-transplant phase lead well acute GVHD prevention . It study AUC-based target MMF pediatric patient undergo myeloablative allogeneic BMT . We propose novel continuous infusion method MMF administration achieve total MPA steady state concentration . Salient finding emerge study examine replicate cohort pediatric adult patient undergoing allo-BMT .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patients must 6 month 21 year age . Recipients allogeneic blood marrow transplant ( BMT ) . Stem cell source bone marrow umbilical cord blood . Bone marrow cord blood unit : Sibling HLA match A , B DRB1 locus . Unrelated cord blood unit minimum 4/6 match allele level HLA A , B DRB1 locus . Unrelated donor HLA allele level match A , B , C DRB1 locus . Minimum prefreezing nucleate cell dose cord blood unit : 3x10^7/kg malignant disease 5x10^7/kg nonmalignant disease . Conditioning regimen must myeloablative intensity . Examples include limited Cy/TBI , BuCy 200 , etc . Patients ≥ 16 year old must Karnofsky score ≥ 70 % , patient &lt; 16 year old must Lansky score ≥ 70 % . Renal : Creatinine clearance radioisotope GFR ≥ 70 mL/min/1.73 m2 . Hepatic : Total bilirubin ≤ 2.5 mg/dL unless increase bilirubin attributable Gilbert 's syndrome ; SGOT ( AST ) , SGPT ( ALT ) , Alkaline Phosphatase &lt; 5 x upper limit normal ( ULN ) age . Cardiac : Left ventricular ejection fraction rest &gt; 40 % , shorten fraction &gt; 26 % , echocardiogram radionuclide scan . Pulmonary : FEV1 , FVC , DLCO ( diffusion capacity ) &gt; 50 % predict ( correct hemoglobin ) ; unable perform pulmonary function test , O2 saturation &gt; 92 % room air . Patients know hypersensitivity MMF . Prior autologous allogeneic BMT &lt; 12 month prior enrollment . Mismatched related donor . Mismatched unrelated marrow donor . Peripheral blood stem cell source . Reduced intensity conditioning . Uncontrolled bacterial , viral , fungal infection . Evidence HIV infection HIV positive serology . Requirement supplemental oxygen . Patients pregnant ( BhCG positive ) breastfeeding . All females 11 year age old and/or begin menstruate screen hCG either urinalysis blood sample order screen pregnancy status , per institutional BMT policy .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Allogeneic blood marrow transplantation ( BMT )</keyword>
	<keyword>Graft versus host disease</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>